VTGN’s Stock Rollercoaster: 16.14% gain in 6 Months, surged 11.45% in 5 Days

A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. Until today this year the stock’s price performance recorded a decrease of -2.36%. However, over the last six months, the performance has been weaker by 16.14%. The price of VTGN increased 30.31% over the last 30 days. And in the last five days, it has surged by 11.45%.

Vistagen Therapeutics Inc (VTGN) current stock price is $3.31. During the last trading session, the stock soared, reaching $15.0 after opening at $3.31. The stock’s lowest point was $12.0 before it closed at $2.95.

Vistagen Therapeutics Inc’s stock market performance has been consistent. The 1-year high for the company’s stock was recorded at $3.79 on 08/23/24, with the lowest value being $1.90 on 04/09/25.

52-week price history of VTGN Stock

The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Vistagen Therapeutics Inc’s current trading price is -12.66% away from its 52-week high, while its distance from the 52-week low is 74.21%. The stock’s price range for this period has been between $1.90 and $3.79. The Healthcare sector company’s shares saw a trading volume of about 5.24 million for the day, which was higher than the average daily volume of 0.3 million over the last three months.

The Connection Between Financial Performance and Market Capitalization

Vistagen Therapeutics Inc (VTGN) has experienced a quarterly rise of 43.91% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 101.55M and boasts a workforce of 57 employees.

Expert Opinions: Analysts’ Ratings for Vistagen Therapeutics Inc

As of right now, 3 analysts are rating Vistagen Therapeutics Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.

How Moving Averages and Trading Volume Data Work Together

Based on Barchart.com data, the company’s moving average over the 100-day period was 2.42, with a change in price of +0.40. Similarly, Vistagen Therapeutics Inc recorded 282,143 in trading volume during the last 100 days, posting a change of +13.75%.

VTGN’s Debt-to-Equity Ratio: A Comprehensive Review

A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for VTGN stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.01.

VTGN Stock Stochastic Average

As of today, the raw stochastic average of Vistagen Therapeutics Inc over the past 50 days is 97.16%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 95.29%. Additionally, the Stochastic %K and %D values for the company were 69.87% and 60.77%, respectively, over the past 20 days.

Invest Chronicle
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.